Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538285 · ClinicalTrials.gov registry record · Phase 2
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
A Phase 2 study of Methamphetamine Use Disorder, sponsored by Nicky Mehtani, MD, MPH.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06538285: Recruiting Phase 2 study of Methamphetamine Use Disorder, sponsored by Nicky Mehtani, MD, MPH.
NCT06538285 is a Phase 2 study of Methamphetamine Use Disorder that is actively recruiting participants, run by Nicky Mehtani, MD, MPH. The registered enrollment target is 12 participants, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538285, a Phase 2 study of Methamphetamine Use Disorder, is actively recruiting participants, sponsored by Nicky Mehtani, MD, MPH.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: * Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? * Is IM ketamine safe and tolerable among patients with MeUD? Participants will: * Receive 3 monitored doses of IM ketamine * Have 3 preparation and 4 integration psychotherapy visits * Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention
Primary Outcome
Binary trial feasibility outcome of whether prospective participants undergoing in-person screening (V0) are found to be fully eligible and ultimately enroll in the study (V1).
Conditions Studied
Interventions
- DRUG Ketamine
- BEHAVIORAL Psychotherapy
Study Locations (1)
California
- San Francisco Department of Public Health - San Francicso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06538285 shows while recruiting
NCT06538285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Methamphetamine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT06538285 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06538285 about?
NCT06538285 is a clinical study titled "Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV". The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer a...
What is the current status of trial NCT06538285?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2025-03-04. Estimated completion is 2026-06.
What conditions does trial NCT06538285 study?
This clinical trial studies the following conditions: Methamphetamine Use Disorder.
What interventions are being tested in trial NCT06538285?
The interventions under investigation include: Ketamine (DRUG), Psychotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06538285?
This trial is sponsored by Nicky Mehtani, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538285 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06538285's enrollment target sits among peer trials
12 11th of 12 higher than 1 of 12 other Methamphetamine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tirzepatide for Obesity and Meth Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
COMPLETED · Phase 2
-
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
RECRUITING · NA
-
Deep TMS of Neural Circuits Associated With Stimulant Use Disorder
RECRUITING · NA
-
Non-Abstinence Outcomes in Methamphetamine Use Disorder
RECRUITING · NA
-
Methamphetamine and Troriluzole
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI